M&A

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

By

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

Precision for Medicine receives $75 million investment

By

Private equity firm TPG Growth invested in the healthcare services company, which plans to use the funds to expand its capabilities and reach.

Pfizer and Allergan merger to create uncertainty for agencies, execs say

Pfizer and Allergan merger to create uncertainty for agencies, execs say

By

The deal not only creates the world's largest drugmaker but also one of the world's largest advertisers.

Accenture acquires Swiss pharma agency, adds digital marketing expertise

Accenture acquires Swiss pharma agency, adds digital marketing expertise

By

The consultancy purchased Boomerang Pharmaceutical Communications, its sixth acquisition in the past 12 months.

Five things for pharma marketers to know: Friday, December 4, 2015

Five things for pharma marketers to know: Friday, December 4, 2015

By

Pharma M&A expected to continue in 2016; Mylan receives government subpoena about marketing and pricing for doxycycline; KaloBios acquired rights to experimental drug to treat Chagas disease

Pfizer, Allergan to merge, creating pharma giant

Pfizer, Allergan to merge, creating pharma giant

By

The deal is estimated to bring in $2 billion in operational synergies, in addition to further commercializing Allergan's products outside the US.

Five things for pharma marketers to know: Monday, November 23, 2015

Five things for pharma marketers to know: Monday, November 23, 2015

By

Pfizer/Allergan merger creates world's largest drugmaker; Turing cuts Daraprim price for hospitals; CVS to cover Amgen's PCSK9 inhibitor

Five things for pharma marketers to know: Friday, November 20

Five things for pharma marketers to know: Friday, November 20

By

AstraZeneca and Sanofi to share compounds in rare agreement; FDA advisory committee votes against bladder cancer drug; Allergan may buyer in Pfizer deal

Five things for pharma marketers to know: Thursday, November 19, 2015

Five things for pharma marketers to know: Thursday, November 19, 2015

By

Pfizer reportedly nears deal with Allergan; health insurers are to blame for rising healthcare costs, according to report; a new fund seeks to invest in digital bio start-ups

Five things for pharma marketers to know: Monday, November 2, 2015

Five things for pharma marketers to know: Monday, November 2, 2015

By

Shire said it will acquire Dyax, which markets Kalbitor; Citron doesn't plan to release any additional allegations against Valeant; Myriad Genetics launches social-media campaign

Five things for pharma marketers to know: Thursday, October 29, 2015

Five things for pharma marketers to know: Thursday, October 29, 2015

By

Pfizer in merger talks with Allergan; comparative effectiveness council says PCSK9s aren't worth the money; pharmacy tied to Valeant used "back-door" sales tactics

Five things for pharma marketers to know: Wednesday, October 28, 2015

Five things for pharma marketers to know: Wednesday, October 28, 2015

By

Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy

Five things for pharma marketers to know: Wednesday, October 14, 2015

Five things for pharma marketers to know: Wednesday, October 14, 2015

By

J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies

Five things for pharma marketers to know: Wednesday, September 16, 2015

Five things for pharma marketers to know: Wednesday, September 16, 2015

By

Obama nominates Robert Califf as FDA commissioner; The Huffington Post debuts investigative series on J&J; Amgen acquires cholesterol-lowering drug

Five things for pharma marketers to know: Tuesday, September 8, 2015

Five things for pharma marketers to know: Tuesday, September 8, 2015

By

Roche CEO sounds off on UK health system cost controls; Concordia Healthcare buys rare-disease drugmaker; Cipla acquires two generic drugmakers

Five things for pharma marketers to know: Thursday, September 3, 2015

Five things for pharma marketers to know: Thursday, September 3, 2015

By

Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Inovalon scoops up consultancy Avalere Health

Inovalon scoops up consultancy Avalere Health

By

The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

By

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

By

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Havas Health acquires London-based PR shop

Havas Health acquires London-based PR shop

By

Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

By

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Monday, June 22

Five things for pharma marketers to know: Monday, June 22

By

AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.

Five things for pharma marketers to know: Wednesday, June 17

Five things for pharma marketers to know: Wednesday, June 17

By

Allergan acquires double-chin treatment manufacturer, Kythera, for $2.1 billion; Valeant eyes acquisition of Egyptian drugmaker; worldwide drug sales could reach $1 trillion by 2020

Five things for pharma marketers to know: Monday, June 8

Five things for pharma marketers to know: Monday, June 8

By

Novartis CEO says pharma must regulate itself; Shire reportedly is in talks to buy biotech Actelion; Lilly insulin outperforms Lantus although safety concerns remain

Four Communications acquires MSA Media

UK indie shop buys healthcare specialist agency to strengthen media-planning business.

Five things for pharma marketers to know: Tuesday, May 19

Five things for pharma marketers to know: Tuesday, May 19

By

Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

By

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Five things for pharma marketers to know: Monday, May 11

Five things for pharma marketers to know: Monday, May 11

By

Mylan weighs Teva takeover; GSK and UNC launch research center and drug company; FDA approves Roche colorectal cancer drug diagnostic

Pharma M&A activity reaches new heights this year

Pharma M&A activity reaches new heights this year

By

Spurred by consolidation, the life sciences industry spent more money on acquisitions in the first quarter than it did in all of 2014 combined.

Email Newsletters